Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Recurrent gene fusions involving oncogenic ETS transcription factors (including ERG, ETV1, and ETV4) have been identified in a large fraction of prostate cancers. The most common fusions contain the 5′ untranslated region of TMPRSS2 fused to ERG. Recently, we identified additional 5′ partners in ETV1 fusions, including TMPRSS2, SLC45A3, HERV-K_22q11.23, C15ORF21, and HNRPA2B1. Here, we identify ETV5 as the fourth ETS family member involved in recurrent gene rearrangements in prostate cancer. Characterization of two cases with ETV5 outlier expression by RNA ligase–mediated rapid amplification of cDNA ends identified one case with a TMPRSS2:ETV5 fusion and one case with a SLC45A3:ETV5 fusion. We confirmed the presence of these fusions by quantitative PCR and fluorescence in situ hybridization. In vitro recapitulation of ETV5 overexpression induced invasion in RWPE cells, a benign immortalized prostatic epithelial cell line. Expression profiling and an integrative molecular concepts analysis of RWPE-ETV5 cells also revealed the induction of an invasive transcriptional program, consistent with ERG and ETV1 overexpression in RWPE cells, emphasizing the functional redundancy of ETS rearrangements. Together, our results suggest that the family of 5′ partners previously identified in ETV1 gene fusions can fuse with other ETS family members, suggesting numerous rare gene fusion permutations in prostate cancer. [Cancer Res 2008;68(1):73–80]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Chromosomal rearrangements that result in the overexpression of members of the PEA3 subfamily (ETV1, ETV4, or ETV5) are found less frequently (36, 170, 171).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Self-citationONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationGene expression profiling identifies clinically relevant subtypes of prostate cancer
Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., Ferrari, M., Egevad, L., Rayford, W., Bergerheim, U., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304146101 · Cited by 1,292
Integrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922 · cited 2×
“Signatures were loaded into the Oncomine Concepts Map(4) for analysis as described (4, 13, 14).”
MethodSelf-citationDistinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844 · cited 8×
“the GeneRacer RLM-RACE kit (Invitrogen) according to the manufacturer’s instructions as described (1, 2, 4).”
BackgroundMethodResultSelf-citationTMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
Demichelis, F., Fall, K., Perner, S., Andrén, O., Schmidt, F., Setlur, S. R., Hoshida, Y., Mosquera, J.-M., Pawitan, Y., Lee, C., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210237 · Cited by 645 · cited 1×
“In previous studies, >95% of cases with ERG or ETV1 outlier expression harbored chromosomal rearrangements (1, 2, 4, 15), suggesting that rearrangements similarly cause ETV5 outlier expression.”
BackgroundSelf-citationGene expression profiling predicts clinical outcome of prostate cancer
Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M., & Gerald, W. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20032 · Cited by 479
TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer
Tomlins, S. A., Mehra, R., Rhodes, D. R., Smith, L. R., Roulston, D., Helgeson, B. E., Cao, X., Wei, J. T., Rubin, M. A., Shah, R. B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0168 · Cited by 469 · cited 4×
“Previously, we used an exon-walking quantitative PCR strategy that showed loss of outlier expression at the 5¶ end of the ETS transcript in cases that harbored gene fusions (1, 2).”
BackgroundMethodSelf-citationWang, J., Cai, Y., Ren, C., & Ittmann, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1966 · Cited by 404 · cited 2×
“Importantly, expression of TMPRSS2:ERG isoforms that encode a fusion production has been associated with more aggressive prostate cancers (20).”
BackgroundVanaja, D. K., Cheville, J. C., Iturria, S., & Young, C. Y. F. (2003) · PubMed · Cited by 334
Cited by
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,234
“This chain (found in sample PR-2832) contained breakpoint pairs at the following loci: (1) 60 bp from exon 6 of TANK binding kinase 1 (TBK1 or ‘NF-kB-activating kinase’)(29); (2) within the first intron of TP53 (7 kilobases (kb) upstream of translation start); (3) 51 kb from MAP2K4 (a kinase recently shown to induce a…”
Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer
Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., Cao, Q., Prensner, J. R., Rubin, M. A., Shah, R. B., et al. (2008) · Neoplasia · doi:10.1593/neo.07822 · Cited by 690
“3 , C15ORF21 , and HNRPA2B1 [3,22].”
InfluentialSelf-citationRecurrent gene fusions in prostate cancer
Kumar-Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2402 · Cited by 664
Self-citationAberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., et al. (2009) · Nature Genetics · doi:10.1038/ng.370 · Cited by 659
“Additionally, ETS family members ETV1 , ETV4 and ETV5 have been shown to be genetically rearranged to either androgen-regulated or ubiquitous promoter regions, resulting in their aberrant expression in prostate cance”
BackgroundPolycomb group proteins: navigators of lineage pathways led astray in cancer
Bracken, A. P., & Helin, K. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2736 · Cited by 523
Metadata
- Authors
- Helgeson, B. E., Tomlins, S. A., Shah, N., Laxman, B., Cao, Q., Prensner, J. R., Cao, X., Singla, N., Montie, J. E., Varambally, S., Mehra, R., & Chinnaiyan, A. M.
- Affiliations
- Michigan Center for Translational Pathology (US)
- University of Michigan (US)
- ORCID
- Venue
- Cancer Research
- Published
- 2008-01-01
- Volume
- 68
- Issue
- 1
- Pages
- 73-80
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1988305905
- Cited by
- 276
- References
- 22
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 14 · 2022: 7 · 2021: 7 · 2020: 9 · 2019: 7 · 2018: 10 · 2017: 11 · 2016: 10 · 2015: 15 · 2014: 17 · 2013: 30 · 2012: 27
- FWCI
- 32.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH)
- Prostate Cancer Foundation
- University of Michigan (P50CA69568)
- National Institutes of Health (W81XWH)
- National Cancer Institute (UO1 CA111275-01, P50-CA-69568, U01CA111275, P50CA069568, R01CA102872)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- ETV5, ETS transcription factors, prostate cancer, gene fusion, TMPRSS2-ERG fusion, ETV1, tumor invasion, functional redundancy, gene rearrangement
- MeSH terms
- Humans, Male, Prostatic Neoplasms, Tumor Cells, Cultured, Oncogene Proteins, Fusion, Gene Expression Profiling, Cell Line, Tumor, Oncogene Fusion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-5352
- The paper
- Helgeson, B. E., Tomlins, S. A., Shah, N., Laxman, B., Cao, Q., Prensner, J. R., Cao, X., Singla, N., Montie, J. E., Varambally, S., Mehra, R., & Chinnaiyan, A. M. (2008). Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-5352
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.